Freenome Raises $270M In Series C, Accelerates Trial For Colorectal Cancer Test
Funding will accelerate an FDA registrational study of the company's first liquid biopsy product, as competition increases in early cancer detection.
You may also be interested in...
CEO sees Guardant360 CDx approval as "watershed moment" for liquid biopsy and plans more biopharma partnerships.
Liquid biopsy company Grail raised $390m in a fourth round of financing, bringing the total funding to $1.9bn.
Since receiving approval for the first broad-panel diagnostic test as a combination product to detect cancer, Foundation Medicine has ramped up its partnerships with pharmaceutical companies and other stakeholders. The company expects to receive a similar approval for a broad-panel liquid biopsy genomic test in the first half of 2020.